Form 8-K - Current report:
SEC Accession No. 0001628280-21-000418
Filing Date
2021-01-13
Accepted
2021-01-13 07:00:22
Documents
16
Period of Report
2021-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20210113.htm   iXBRL 8-K 34525
2 EX-99.1 exhibit991pre-earningsrele.htm EX-99.1 22648
8 tm2026634d1_ex99-1img001a0a.jpg GRAPHIC 5932
  Complete submission text file 0001628280-21-000418.txt   217560

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20210113.xsd EX-101.SCH 2436
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT espr-20210113_cal.xml EX-101.CAL 722
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT espr-20210113_def.xml EX-101.DEF 1659
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20210113_lab.xml EX-101.LAB 24993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20210113_pre.xml EX-101.PRE 13202
9 EXTRACTED XBRL INSTANCE DOCUMENT espr-20210113_htm.xml XML 10983
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 21525048
SIC: 2834 Pharmaceutical Preparations